Basilea News Basilea News en Wed, 26 Oct 2016 11:15:26 +0200 Wed, 26 Oct 2016 11:15:26 +0200 Chameleon CMS (Webmaster Webmaster) (Webmaster Webmaster) <![CDATA[Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries]]> Tue, 20 Sep 2016 07:15:00 +0200 <![CDATA[Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma]]>
  • Basilea grants Asahi Kasei Pharma exclusive license to develop and commercialize isavuconazole in Japan
  • Basilea eligible for upfront and milestone payments of up to CHF 67 million and double-digit royalties

  • ]]>
    Thu, 15 Sep 2016 07:15:00 +0200
    <![CDATA[Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America]]> Tue, 13 Sep 2016 07:15:00 +0200 <![CDATA[Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553]]> Tue, 06 Sep 2016 07:15:00 +0200 <![CDATA[Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region]]>
  • Basilea extending its agreement with Hikma to include antifungal CRESEMBA® in addition to antibiotic Zevtera®
  • ]]>
    Wed, 17 Aug 2016 07:15:00 +0200
    <![CDATA[Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets]]>
  • Antifungal CRESEMBA® (isavuconazole) launched in first European markets
  • Entered contract with BARDA for the development and potential US registration of the antibiotic ceftobiprole (European trade name Zevtera® or Mabelio®)
  • Half-year cash and financial investments of CHF 311 million
  • ]]>
    Mon, 15 Aug 2016 07:15:00 +0200
    <![CDATA[Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy]]> Mon, 27 Jun 2016 07:15:00 +0200 <![CDATA[Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting]]>
  • Clinical data reported from completed phase 1/2a study of BAL101553, with once-weekly 2-hour infusion showing signals of clinical activity
  • Design of ongoing phase 1/2a study with once-daily oral BAL101553 presented, with four dose cohorts completed
  • Design of ongoing BAL3833 oral phase 1 study presented, with four dose cohorts completed
  • ]]>
    Thu, 09 Jun 2016 07:15:00 +0200
    <![CDATA[Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders]]> Thu, 21 Apr 2016 18:30:10 +0200 <![CDATA[Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting]]>
  • Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment
  • PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models
  • ]]>
    Thu, 21 Apr 2016 07:15:00 +0200